Last reviewed 2026-04-20 · How we verify

Disida (DISOFENIN)

Phase 2 active Small molecule

Disida (generic name: DISOFENIN) is a disofenin drug. It is currently in Phase 2 development.

Disida works by binding to a specific target, but the identity of this target is unknown.

Disida (DISOFENIN) is a small molecule drug of the disofenin class, but specific details about its target, pharmacokinetics, and commercial status are not available. It is unclear whether Disida has been approved by the FDA or is available as a generic medication. The exact indications for Disida are also unknown. Further research is needed to determine the safety and efficacy of Disida. As a result, it is not possible to provide a comprehensive summary of Disida's commercial status or key safety considerations.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DISOFENIN
Drug class	disofenin
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Disida has a key that fits into one of these locks. When Disida binds to its target, it can either block or enhance the activity of the cell, depending on the specific mechanism of action. However, without knowing the identity of the target, it's difficult to understand exactly how Disida works.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Disida CI brief — competitive landscape report
Disida updates RSS · CI watch RSS

Frequently asked questions about Disida

What is Disida?

Disida (DISOFENIN) is a disofenin drug.

How does Disida work?

Disida works by binding to a specific target, but the identity of this target is unknown.

What is the generic name of Disida?

DISOFENIN is the generic (nonproprietary) name of Disida.

What drug class is Disida in?

Disida belongs to the disofenin class. See all disofenin drugs at /class/disofenin.

What development phase is Disida in?

Disida is in Phase 2.

Drug class: All disofenin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing